ArchivesMagazine - 11 Jun 2020The story behind a rumoured AstraZeneca and Gilead merger Over the last five years AstraZeneca’s shares have almost doubled while Gilead’s have dropped by a third 11 June 2020|News|by Martin Gamble Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Dangers signs from the current share rally Why the UK market has lagged behind > Issue: 11 Jun 2020 - Page 6 | Contents Next: Why the UK market has lagged behind Previous: Dangers signs from the current share rally Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Martin Gamble Issue Contents Ask Tom How does taking a defined benefit pension before 2006 impact your lifetime allowance? Case study How I invest: rebuilding an ISA to save for retirement Editor's View Volatility in the oil market looks set to continue Feature Four funds to own in retirement First-time Investor How to maintain a portfolio Great Ideas Drive for efficiency in US healthcare is great for Craneware Buy pawnbroker H&T as it gets back to business Begbies’ shares climb on personal insolvency deal Applegreen profit is ripe for picking News The story behind a rumoured AstraZeneca and Gilead merger Dangers signs from the current share rally Airlines quarantine backlash as BA owner feels heat over staff plans Capex cuts matter to investors Personal Finance The impact of Covid-19 on the property market Russ Mould Why the UK market has lagged behind Under The Bonnet Just do it: why you should invest in Nike Your Questions Answered Which should I choose, tracker funds or ETFs?
